

Martin P BÃ©hÃ©

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2926700/publications.pdf>

Version: 2024-02-01

84
papers

3,965
citations

109321

35
h-index

128289

60
g-index

87
all docs

87
docs citations

87
times ranked

3717
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeted Radiotherapeutics from 'Bench-to-Bedside'. <i>Chimia</i> , 2022, 74, 939.	0.6	5
2	A Multispecific Anti-CD40 DARPIn Construct Induces Tumor-Selective CD40 Activation and Tumor Regression. <i>Cancer Immunology Research</i> , 2022, 10, 626-640.	3.4	9
3	EANM guideline on quality risk management for radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3353-3364.	6.4	11
4	1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 585-592.	2.8	13
5	Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin ¹⁷⁷ Lu-PP-F11N. <i>Cancers</i> , 2021, 13, 2629.	3.7	8
6	Exploring the signaling space of a GPCR using bivalent ligands with a rigid oligoproline backbone. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	5
7	Therapeutic Response of CCKBR-Positive Tumors to Combinatory Treatment with Everolimus and the Radiolabeled Minigastrin Analogue [¹⁷⁷ Lu]Lu-PP-F11N. <i>Pharmaceutics</i> , 2021, 13, 2156.	4.5	4
8	Cholecystokinin 2 Receptor Agonist ¹⁷⁷ Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 520-526.	5.0	53
9	Biodistribution of Site-Specific PEGylated Fibroblast Growth Factor-2. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 425-432.	5.2	13
10	Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [¹⁷⁷ Lu]Lu-PP-F11N. <i>Theranostics</i> , 2020, 10, 10861-10873.	10.0	15
11	Distance-Dependent Cellular Uptake of Oligoproline-Based Homobivalent Ligands Targeting GPCRs – An Experimental and Computational Analysis. <i>Bioconjugate Chemistry</i> , 2020, 31, 2431-2438.	3.6	5
12	New Insights into Arrestin Recruitment to GPCRs. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4949.	4.1	9
13	Fibronectin fibers are highly tensed in healthy organs in contrast to tumors and virus-infected lymph nodes. <i>Matrix Biology Plus</i> , 2020, 8, 100046.	3.5	19
14	Evaluation of Actinium-225 Labeled Minigastrin Analogue [²²⁵ Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy. <i>Pharmaceutics</i> , 2020, 12, 1088.	4.5	19
15	Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4484-4495.	6.4	20
16	Design of Radiolabeled Analogs of Minigastrin by Multiple Amide-to-Triazole Substitutions. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 4496-4505.	6.4	20
17	Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog ¹⁷⁷ Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 393-399.	5.0	42
18	Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting. <i>Molecular Pharmaceutics</i> , 2019, 16, 3760-3769.	4.6	17

#	ARTICLE	IF	CITATIONS
19	Comparison of desferrioxamine and NODAGA for the gallium-68 labeling of exendin-4. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 9.	3.9	10
20	Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. <i>Journal of Controlled Release</i> , 2019, 307, 379-392.	9.9	22
21	Exendin-4 analogs in insulinoma theranostics. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 656-672.	1.0	54
22	Elucidating the Structure-Activity Relationship of the Pentaglutamic Acid Sequence of Minigastrin with Cholecystokinin Receptor Subtype 2. <i>Bioconjugate Chemistry</i> , 2019, 30, 657-666.	3.6	12
23	Succinylated Gelatin Improves the Theranostic Potential of Radiolabeled Exendin-4 in Insulinoma Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 812-816.	5.0	21
24	Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and <i>In Vivo</i> Beta Cell Imaging. <i>Molecular Pharmaceutics</i> , 2018, 15, 486-494.	4.6	8
25	Radiosynthesis and evaluation of an ¹⁸ F-labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2018, 3, 1.	3.9	11
26	Prostate cancer imaging and therapy. , 2018, , .		0
27	Radiolabeled ¹¹¹ In-FGF-2 Is Suitable for <i>In Vitro</i> / <i>Ex Vivo</i> Evaluations and <i>In Vivo</i> Imaging. <i>Molecular Pharmaceutics</i> , 2017, 14, 639-648.	4.6	4
28	Targets and probes for non-invasive imaging of β^2 -cells. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 712-727.	6.4	32
29	Methoxinine - an alternative stable amino acid substitute for oxidation-sensitive methionine in radiolabelled peptide conjugates. <i>Journal of Peptide Science</i> , 2017, 23, 38-44.	1.4	11
30	Dual, Site-Specific Modification of Antibodies by Using Solid-Phase Immobilized Microbial Transglutaminase. <i>ChemBioChem</i> , 2017, 18, 1923-1927.	2.6	51
31	Novel peptide probes to assess the tensional state of fibronectin fibers in cancer. <i>Nature Communications</i> , 2017, 8, 1793.	12.8	31
32	Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy. <i>Cellular Signalling</i> , 2016, 28, 1412-1421.	3.6	48
33	Self-assembled gold coating enhances X-ray imaging of alginate microcapsules. <i>Nanoscale</i> , 2015, 7, 2480-2488.	5.6	12
34	Evaluation of ¹¹¹ In-Labelled Exendin-4 Derivatives Containing Different Meprin β^2 -Specific Cleavable Linkers. <i>PLoS ONE</i> , 2015, 10, e0123443.	2.5	20
35	Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E692-E701.	7.1	83
36	Non-invasive quantification of the beta cell mass by SPECT with ¹¹¹ In-labelled exendin. <i>Diabetologia</i> , 2014, 57, 950-959.	6.3	129

#	ARTICLE	IF	CITATIONS
37	A comparison of three ^{67/68} Ga-labelled exendin-4 derivatives for β^2 -cell imaging on the GLP-1 receptor: the influence of the conjugation site of NODAGA as chelator. <i>EJNMMI Research</i> , 2014, 4, 31.	2.5	31
38	Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 615-620.	1.0	44
39	⁶⁴ Cu- and ⁶⁸ Ga-Labelled [Nle ¹⁴ ,Lys ⁴⁰ (Ahx-NODAGA)NH ₂]-Exendin-4 for Pancreatic Beta Cell Imaging in Rats. <i>Molecular Imaging and Biology</i> , 2014, 16, 255-263.	2.6	55
40	Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 115-122.	11.4	153
41	Multifactorial diagnostic NIR imaging of CCK2R expressing tumors. <i>Biomaterials</i> , 2013, 34, 5172-5180.	11.4	21
42	Effect of long-term treatment with pramipexole or levodopa on presynaptic markers assessed by longitudinal [¹²³ I]FP-CIT SPECT and histochemistry. <i>NeuroImage</i> , 2013, 79, 191-200.	4.2	12
43	Inflammatory neovascularization during graft-versus-host disease is regulated by β integrin and miR-100. <i>Blood</i> , 2013, 121, 3307-3318.	1.4	75
44	Distribution, Elimination, and Renal Handling of ^{99m} Tc-Demogastrin 1. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 169-174.	1.0	1
45	Optical Imaging of CCK2/Gastrin Receptor-Positive Tumors With a Minigastrin Near-Infrared Probe. <i>Investigative Radiology</i> , 2011, 46, 196-201.	6.2	12
46	First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1412-1417.	5.0	157
47	Activated Platelets in Carotid Artery Thrombosis in Mice Can Be Selectively Targeted with a Radiolabeled Single-Chain Antibody. <i>PLoS ONE</i> , 2011, 6, e18446.	2.5	24
48	In vivo testing of ¹⁷⁷ Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer. <i>In Vivo</i> , 2011, 25, 55-9.	1.3	16
49	Non-Invasive In Vivo Imaging of Tumor-Associated CD133/Prominin. <i>PLoS ONE</i> , 2010, 5, e15605.	2.5	36
50	Exendin-4-Based Radiopharmaceuticals for Glucagonlike Peptide-1 Receptor PET/CT and SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1059-1067.	5.0	141
51	Scintigraphic assessment of salivary gland function in a rat model. <i>In Vivo</i> , 2010, 24, 681-5.	1.3	3
52	Stability of siRNA polyplexes from poly(ethylenimine) and poly(ethylenimine)-g-poly(ethylene glycol) under in vivo conditions: Effects on pharmacokinetics and biodistribution measured by Fluorescence Fluctuation Spectroscopy and Single Photon Emission Computed Tomography (SPECT) imaging. <i>Journal of Controlled Release</i> , 2009, 138, 148-159.	9.9	173
53	Peripheral and central biodistribution of ¹¹¹ In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease. <i>Neuroscience Letters</i> , 2009, 449, 240-245.	2.1	30
54	In Vivo SPECT and Real-Time Gamma Camera Imaging of Biodistribution and Pharmacokinetics of siRNA Delivery Using an Optimized Radiolabeling and Purification Procedure. <i>Bioconjugate Chemistry</i> , 2009, 20, 174-182.	3.6	97

#	ARTICLE	IF	CITATIONS
55	Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1868-1877.	6.4	87
56	HER2 Targeted Polyplexes: The Effect of Polyplex Composition and Conjugation Chemistry on in Vitro and in Vivo Characteristics. <i>Bioconjugate Chemistry</i> , 2008, 19, 244-253.	3.6	16
57	Indication for Different Mechanisms of Kidney Uptake of Radiolabeled Peptides. <i>Journal of Nuclear Medicine</i> , 2007, 48, 596-601.	5.0	150
58	[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma. <i>Clinical Cancer Research</i> , 2007, 13, 3696-3705.	7.0	92
59	Crosslinked nanocarriers based upon poly(ethylene imine) for systemic plasmid delivery: In vitro characterization and in vivo studies in mice. <i>Journal of Controlled Release</i> , 2007, 118, 370-380.	9.9	98
60	Bioreversibly crosslinked polyplexes of PEI and high molecular weight PEG show extended circulation times in vivo. <i>Journal of Controlled Release</i> , 2007, 124, 69-80.	9.9	110
61	Lokalisation von Gastrinomen mit nuklearmedizinischen Methoden. <i>Wiener Klinische Wochenschrift</i> , 2007, 119, 593-596.	1.9	16
62	Biodistribution and elimination characteristics of two 111In-labeled CCK-2/gastrin receptor-specific peptides in rats. <i>Anticancer Research</i> , 2007, 27, 907-12.	1.1	11
63	Trastuzumab~Polyethylenimine~Polyethylene Glycol Conjugates for Targeting Her2-Expressing Tumors. <i>Bioconjugate Chemistry</i> , 2006, 17, 1190-1199.	3.6	64
64	A new technique for in vivo imaging of specific GLP-1 binding sites: First results in small rodents. <i>Regulatory Peptides</i> , 2006, 137, 162-167.	1.9	77
65	Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2006, 13, 1203-1211.	3.1	55
66	[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting. <i>Journal of Nuclear Medicine</i> , 2006, 47, 2025-33.	5.0	123
67	GnRH-II receptor-like antigenicity in human placenta and in cancers of the human reproductive organs. <i>European Journal of Endocrinology</i> , 2005, 153, 605-612.	3.7	29
68	Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1012-5.	5.0	63
69	Evaluation of [99mTc/EDDA/HYNIC]octreotide derivatives compared with [111In-DOTA0,Tyr3,Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1561-9.	5.0	66
70	CCK-2/gastrin receptor-targeted tumor imaging with (99m)Tc-labeled minigastrin analogs. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1727-36.	5.0	72
71	Two Technetium-99m-Labeled Cholecystokinin-8 (CCK8) Peptides for Scintigraphic Imaging of CCK Receptors. <i>Bioconjugate Chemistry</i> , 2004, 15, 561-568.	3.6	43
72	18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. <i>Nuclear Medicine Communications</i> , 2004, 25, 439-443.	1.1	50

#	ARTICLE	IF	CITATIONS
73	Improved kinetic stability of DTPA-dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1140-1146.	6.4	67
74	Imaging Lung Tumors with Peptide-Based Radioligands. <i>Clinical Lung Cancer</i> , 2003, 5, 119-124.	2.6	9
75	Influence of Somatostatin Receptor Scintigraphy and CT/MRI on the Clinical Management of Patients with Gastrointestinal Neuroendocrine Tumors: An Analysis in 188 Patients. <i>Digestion</i> , 2003, 68, 80-85.	2.3	27
76	Radioiodide treatment after sodium iodide symporter gene transfer is a highly effective therapy in neuroendocrine tumor cells. <i>Cancer Research</i> , 2003, 63, 1333-8.	0.9	35
77	Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. <i>Seminars in Nuclear Medicine</i> , 2002, 32, 97-109.	4.6	131
78	Correlation of Red Marrow Radiation Dosimetry with Myelotoxicity: Empirical Factors Influencing the Radiation-Induced Myelotoxicity of Radiolabeled Antibodies, Fragments and Peptides in Pre-Clinical and Clinical Settings. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002, 17, 445-464.	1.0	30
79	Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 597-606.	6.4	95
80	Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment. <i>Expert Review of Anticancer Therapy</i> , 2001, 1, 501-505.	2.4	1
81	Biodistribution, Blood Half-Life, and Receptor Binding of a Somatostatin-Dextran Conjugate. <i>Medical Oncology</i> , 2001, 18, 59-64.	2.5	14
82	Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. , 1998, 75, 406-411.		109
83	Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 424-430.	6.4	99
84	Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 368-371.	2.1	159